Icb Biotechnology Investments Ltd, formerly BSP Biological Signal Processing Ltd, is an Israel-based company engaged in the technology sector. The Company offers products for non-invasive diagnosis and monitoring of Coronary Artery Disease (CAD). The Companyâ€™s products include: the HyperQ EX-300, a 12-lead stress Electrocardiography (ECG) system with the capability to analyze high frequency components of the ECG signal (HyperQ analysis); the HyperQ AD-100, which is a system that integrates with conventional stress ECG machines and provides HyperQ CAD analysis and the HyperQ AN-S OEM product which enables any ECG data acquisition system to enhance its diagnostic capabilities by incorporating HyperQ analysis. HyperQ technology uses a multifaceted process to interpret the information acquired by the ECG hardware. This process includes identification of the QRS complex, rejection of corrupted signals, several alignment procedures, signal to noise enhancement, and filtering.